Применение статинов при кардиоренальном синдроме: возможности лечения и профилактики
https://doi.org/10.17650/1818-8338-2012-3-4-80-84
Аннотация
Сердечно-сосудистые заболевания – главная причина заболеваемости и смертности не только в основной популяции, но и при хронической болезни почек. Возрастающая распространенность хронической болезни почек и хронической сердечной недостаточности способствует увеличению числа случаев кардиоренального синдрома. Среди методов профилактики и лечения кардиоренального синдрома наряду с применением ингибиторов ангиотензинпревращающего фермента, β-адреноблокаторов, антианемических препаратов и диуретиков актуальны и рекомендуются рядом исследований статины. Использование статинов является эффективной мерой профилактики кардиоренального синдрома у пациентов с высоким риском его развития, улучшает качество жизни и выживаемость, а у додиализных больных с хронической болезнью почек может служить вторичной профилактикой кардиоваскулярной смертности.
Список литературы
1. Ronco C., McCullough P., Anker S.D. et al.; Acute Dialysis Quality Initiative (ADQI) consensus group. Cardio-renal syndromes: report from the consensus conference of the acute dialysis quality
2. initiative. Eur Heart J 2010;31(6):703–11.
3. House A.A., Haapio M., Lassus J. et al. Therapeutic strategies for heart failure in cardiorenal syndromes. Am J Kidney Dis 2010;56(4):759–73.
4. Ronco C., House A.A., Haapio M. Cardiorenal syndrome: refining the definition of a complex symbiosis gone wrong. Intensive Care Med 2008;34(5):957–62.
5. Hunt S.A., Abraham W.T., Chin M.H. et al.; American College of Cardiology Foundation; American Heart Association. 2009 Focused update incorporated into the ACC/AHA 2005 Guidelines for the
6. Diagnosis and Management of Heart Failure in Adults A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines Developed in Collaboration With the International Society for Heart and Lung Transplantation. J Am Coll Cardiol 2009;53(15):e1–e90.
7. Forman D.E., Butler J., Wang Y. et al. Incidence, predicators at admission and impact of worsening renal function among patients hospitalized with heart failure. J Am Coll Cardiol 2004;43(1):61–7.
8. Schiffrin E.L., Lipman M.L., Mann J.F. Cardiovascular Involvement in General Medical Conditions. Circulation 2007;116(1):85–97.
9. Koniari K., Nikolaou M., Paraskevaidis I., Parissis J. Therapeutic options for the management of the cardiorenal syndrome. Int J Nephrol 2010;2011:194910.
10. Parikh C.R., Coca S.G., Wang Y. et al. Long-term prognosis of acute kidney injury after acute myocardial infarction. Arch Intern Med 2008;168(9):987–95.
11. Athyros V.G., Katsiki N., Tziomalos K., Karagiannis A. Preventing cardio-renal syndrome rather than treating it: could statins play a role? Open Cardiovasc Med J 2011;5:226–30.
12. Geisberg C., Butler J. Addressing the challenges of cardiorenal syndrome. Cleve Clin J Med 2006;73(5):485–91.
13. Fabbian F., Pala M., De Giorgi A. et al. Clinical features of cardio-renal syndrome in a cohort of consecutive patients admitted to an internal medicine ward. Open Cardiovasc Med J 2011;5:220–5.
14. House А.А. Cardio-renal syndrome type 4: epidemiology, pathophysiology and treatment. Semin Nephrol 2012;32(1):40–8.
15. Bianchi S., Grimaldi D., Bigazzi R. Statins and lipid-lowering strategies in cardiorenal patients. Contrib Nephrol 2011;171:143–50.
16. Epstein M., Vaziri N.D. Statins in the management of dyslipidemia associated with chronic kidney disease. Nat Rev Nephrol 2012;8(4):214–23.
17. McCullough P.A., Haapio M., Mankad S. et al.; Acute Dialysis Quality Initiative (ADQI) Consensus Group. Prevention of cardio-renal syndromes: workgroup statements from the 7th ADQI Consensus Conference. Nephrol Dial Transplant 2010;25(6):1777–84.
18. House A.A., Haapio M., Lassus J. et al. Pharmacological management of cardiorenal syndromes. Int J Nephrol 2011; 2011:630809.
19. Hou F.F., Zhang X., Zhang G.H. et al. Efficacy and safety of benazepril for advanced chronic renal insufficiency. N Engl J Med 2006;354(2):131–40.
20. Butler J., Forman D.E., Abraham W.T. et al. Relationship between heart failure treatment and development of worsening renal function among hospitalized patients. Am Heart J 2004;147(2):331–8.
21. Yorgun H., Deniz A., Aytemir K. Cardiogenic shock secondary to combination of diltiazem and sotalol. Intern Med J 2008;38(3):221–2.
22. Bakris G.L., Hart P., Ritz E. Beta blockers in the management of chronic kidney disease. Kidney Int
23. ;70(11):1905–13.
24. McCullough P.A., Lepor N.E. The deadly triangle of anemia, renal insufficiency, and cardiovascular disease: implications for prognosis and treatment. Rev Cardiovasc Med 2005;6(1):1–10.
25. Pagourelias E.D., Koumaras C., Kakafika A.I. et al. Cardiorenal anemia syndrome: do erythropoietin and iron therapy have a place in the treatment of heart failure? Angiology 2009;60(1):74–81.
26. Solomon S.D., Uno H., Lewis E.F. et al.; Trial to Reduce Cardiovascular Events with Aranesp Therapy (TREAT) Investigators. Erythropoietic response and outcomes in kidney disease and type 2 diabetes. N Engl J Med 2010;363(12):1146–55.
27. Shah R.V., Givertz M.M. Managing acute renal failure in patients with acute decompensated heart failure: the cardiorenal syndrome. Curr Heart Fail Rep 2009;6(3):176–81.
28. Athyros V.G., Karagiannis A., Kakafika A. et al. Statins and renal function. Is the compound and dose making a difference? Nephrol Dial Transplant 2007;22(3):963–4.
29. Kalaitzidis R.G., Elisaf M.S. The role of statins in chronic kidney disease. Am J Nephrol 2011;34(3):195–202.
30. Fellström B., Holdaas H., Jardine A.G. et al.; AURORA Study Group.Cardiovascular disease in patients with renal disease: the role of statins. Curr Med Res Opin 2009;25(1):271–85.
31. Athyros V.G., Mitsiou E.K., Tziomalos K. et al. Impact of managing atherogenic dyslipidemia on cardiovascular outcome across different stages of diabetic nephropathy. Expert Opin Pharmacother
32. ;11(5):723–30.
33. Athyros V.G., Mikhailidis D.P., Papageorgiou A.A. et al.; GREACE Study Collaborative Group. Effect of statins and ACE inhibitors alone and in combination on clinical outcome in patients with coronary
34. heart disease. J Hum Hypertens 2004;18(11):781–8.
35. Sandhu S., Wiebe N., Fried L.F., Tonelli M. Statins for improving renal outcomes: a meta-analysis. J Am Soc Nephrol 2006;17(7):2006–16.
36. Cases A., Coll E. Dyslipidemia and the progression of renal disease in chronic renal failure patients. Kidney Int Suppl 2005;(99):S87–93.
37. Fuiano G., Esposito C., Sepe V. et al. Effects of hypercholesterolemia of renal hemodynamics: study in patients with nephrotic syndrome. Nephron 1996;73(3):430–5.
38. O’Driscoll G., Green D., Taylor R.R. Simvastatin, an HMG-coenzyme A reductase inhibitor, improves endothelial function within 1 month. Circulation 1997;95(5):1126–31.
39. Guijarro C., Keane W.F. Effects of lipids on the pathogenesis of progressive renal failure: role of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors in the prevention of glomerulosclerosis. Miner Electrolyte Metab 1996;22(1–3):147–52.
40. Ridker P.M., Rifai N., Clearfield M. et al.; Air Force/Texas Coronary Atherosclerosis Prevention Study
41. Investigators. Measurement of C-reactive protein for the targeting of statin therapy in the primary prevention of acute coronary events. N Engl J Med 2001;344(26):1959–65.
42. Ferro D., Parrotto S., Basili S. et al. Simvastatin inhibits the monocyte expression of proinflammatory cytokines in patients with hypercholesterolemia. J Am Coll Cardiol 2000;36(2):427–31.
43. Oda H., Keane W.F. Recent advances in statins and the kidney. Kidney Int Suppl 1999;71:S2–5.
44. Fried L.F., Orchard T.J., Kasiske B.L. Effect of lipid reduction on the progression of renal disease: a meta-analysis. Kidney Int 2001;59(1):260–9.
45. Navaneethan S.D., Pansini F., Perkovic V. et al. HMG CoA reductase inhibitors (statins) for people with chronic kidney disease not requiring dialysis. Cochrane Database Syst Rev 2009;(2):CD007784.
46. Колина И.Б., Ставровская Е.В., Шилов Е.М. Дислипидемия и хронические прогрессирующие заболевания почек. Тер архив 2004;76(9):75–8.
47. Lacquaniti A., Bolignano D., Donato V. et al. Alterations of lipid metabolism in chronic nephropathies: mechanisms, diagnosis and treatment. Kidney Blood Press Res 2010;33(2):100–10.
48. Tonelli M., Moyé L., Sacks F.M. et al.; Cholesterol and Recurrent Events Trial Investigators. Effect of pravastatin on loss of renal function in people with moderate chronic renal insufficiency and
49. cardiovascular disease. J Am Soc Nephrol 2003;14(6):1605–13.
50. Athyros V.G., Kakafika A.I., Karagiannis A. et al. Do we need to consider inflammatory markers when we treat atherosclerotic disease? Atherosclerosis 2008;200(1):1–12.
51. Solomon D.H., Karlson E.W., Rimm E.B. et al. Cardiovascular morbidity and mortality in women diagnosed with rheumatoid arthritis. Circulation 2003;107(9):1303–7.
52. Manzi S., Meilahn E.N., Rairie J.E. et al. Age-specific incidence rates of myocardial infarction and angina in women with systemic lupus erythematosus: comparison with the Framingham Study.
53. Am J Epidemiol 1997;145(5):408–15. 46. Abou-Raya A, Abou-Raya S. Inflammation: a pivotal link between autoimmune diseases and atherosclerosis. Autoimmun Rev 2006;5(5):331–7.
54. Costenbader K.H., Desai A., Alarcón G.S. et al. Trends in the incidence, demographics, and outcomes of end-stage renal disease due to lupus nephritis in the US from 1995 to 2006. Arthritis Rheum 2011;63(6):1681–8.
55. Athyros V.G., Kakafika A.I., Tziomalos K. et al. Pleiotropic effects of statins--clinical evidence. Curr Pharm Des 2009;15(5):479–89.
56. Athyros V.G., Katsiki N., Karagiannis A., Mikhailidis D.P. Editorial: should chronic kidney disease be considered as a coronary heart disease equivalent? Curr Vasc Pharmacol 2012;10(3):374–7.
57. European Association for Cardiovascular Prevention & Rehabilitation; Reiner Z., Catapano A.L., De Backer G. et al.; ESC Committee for Practice Guidelines (CPG) 2008–2010 and 2010–2012 Committees. ESC/EAS Guidelines for the management of dyslipidaemias: The Task Force for the
58. management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS). Eur Heart J 2011;32(14):1769–818.
59. Athyros V.G., Mikhailidis D.P., Papageorgiou A.A. et al. A subgroup analysis of the Greek atorvastatin and coronary heart disease evaluation (GREACE) study. The effect of statins versus untreated
60. dyslipidaemia on renal function in patients with coronary heart disease. J Clin Pathol 2004;57(7):728–34.
61. Athyros V.G., Mikhailidis D.P., Liberopoulos E.N. et al. Effect of statin treatment on renal function and serum uric acid levels and their relation to vascular events in patients with coronary heart disease
62. and metabolic syndrome: a subgroup analysis of the GREek Atorvastatin and Coronary heart disease Evaluation (GREACE) Study. Nephrol Dial Transplant 2007;22(1):118–27.
63. Athyros V.G., Papageorgiou A.A., Elisaf M., Mikhailidis D.P.; GREACE Study Collaborative Group. Statins and renal function in patients with diabetes mellitus. Curr Med Res Opin 2003;19(7):615–7.
64. Shepherd J., Kastelein J.J., Bittner V. et al.; TNT (Treating to New Targets) Investigators. Intensive lipid lowering with atorvastatin in patients with coronary heart disease and chronic kidney disease: the TNT (Treating to New Targets) study. J Am Coll Cardiol 2008;51(15):1448–54.
65. Christensen M., Su A.W., Snyder R.W. et al. Simvastatin protection against acute immune-mediated glomerulonephritis in mice. Kidney Int 2006;69(3):457–63.
66. Zoja C., Corna D., Rottoli D. et al. Effect of combining ACE inhibitor and statin in severe experimental nephropathy. Kidney Int 2002;61(5):1635–45.
67. Olbricht C.J., Wanner C., Thiery J., Basten A. Simvastatin in nephrotic syndrome. Simvastatin in Nephrotic Syndrome Study Group. Kidney Int Suppl 1999;71:S113–6.
68. Yukawa S., Mune M., Yamada Y. et al. Ongoing clinical trials of lipid reduction therapy in patients with renal disease. Kidney Int Suppl 1999;71:S141–3.
69. Шестакова М.В., Дедов И.И. Сахарный диабет и хроническая болезнь почек. М.: МИА, 2009.
70. Ponte B., Bourquin V., StoermannChopard C. Statins: what is their place in the treatment of chronic kidney insufficiency? Rev Med Suisse 2009;5(192):463–6.
71. Deshmukh A., Mehta J.L. Statins and renal disease: friend or foe? Curr Atheroscler Rep 2011;13(1):57–63.
72. Fabbian F., De Giorgi A., Pala M. et al. Evidence-based statin prescription for cardiovascular protection in renal impairment. Clin Exp Nephrol 2011;15(4):456–63.
73. Tonelli M., Isles C., Curhan G.C. et al. Effect of pravastatin on cardiovascular events in people with chronic kidney disease. Circulation 2004;110(12): 1557–63.
74. Wanner C., Krane V., März W. et al. Atorvastatin in patients with type 2 diabetes mellitus undergoing hemodialysis. N Engl J Med 2005;353(3):238–48.
75. Fellström B.C., Jardine A.G., Schmieder R.E. et al. Rosuvastatin and cardiovascular events in patients undergoing hemodialysis. N Engl J Med 2009;360(14):1395–407.
76. Baigent C., Landray M.J., Reith C. et al.; SHARP Investigators. The effects of lowering LDL cholesterol with simvastatin plus ezetimibe in patients with chronic kidney disease (Study of Heart and Renal Protection): a randomized placebocontrolled trial. Lancet 2011;377(9784):2181–92.
Рецензия
Для цитирования:
Минасян А.М. Применение статинов при кардиоренальном синдроме: возможности лечения и профилактики. Клиницист. 2012;6(3-4):80-84. https://doi.org/10.17650/1818-8338-2012-3-4-80-84
For citation:
Minasyan A.M. Use of statins in cardiorenal syndrome : possibilities for its treatment and prevention. The Clinician. 2012;6(3-4):80-84. (In Russ.) https://doi.org/10.17650/1818-8338-2012-3-4-80-84
Просмотров: 590
Послать статью по эл. почте 